23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
17:47 , Apr 6, 2018 |  BC Week In Review  |  Company News

Roche aquires remyelination play Inception 5

Roche (SIX:ROG; OTCQX:RHHBY) is exercising its option to acquire Versant Venture’s remyelination play Inception 5 Inc. (San Diego, Calif.). Concurrently, the VC is doubling down on regenerative therapies for neurology through the launch of successor...
12:41 , Apr 4, 2018 |  BC Extra  |  Company News

Roche acquires Versant's MS play Inception 5, VC launches another

Roche (SIX:ROG; OTCQX:RHHBY) is exercising its option to acquire Versant Venture’s remyelination play Inception 5 Inc. Concurrently, the VC is doubling down on regenerative therapies for neurology through the launch of successor company Pipeline Therapeutics...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc. 's anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical...
07:00 , Oct 22, 2015 |  BC Innovations  |  Targets & Mechanisms

Myelin pools

A group at New York University has identified a pool of neural stem cells that could help remyelinate damaged axons in patients with multiple sclerosis (MS). At root is the transcription factor GLI1 , which...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Versant's voyage

Many life science VCs have narrow geographic footprints, but Versant Ventures has instead expanded operations to Canada and Europe, where it believes there are both good research, and untapped opportunities. The firm also is forgoing...
07:00 , Aug 15, 2014 |  BC Innovations  |  Distillery Therapeutics

Multiple sclerosis

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) BET bromodomain proteins In vitro and cell culture studies suggest selective inhibitors of BET bromodomain proteins could be useful for promoting...